GLP1_NEW
Visepegenatide 150 µg injection once weekly
VISEPE_SC_150UG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.57 (-0.92 to -0.22) | 0.24 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.57 (-0.90 to -0.23) | 0.33 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.48 (-3.12 to 2.27) | 0.37 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.73 (-1.07 to -0.39) | 0.29 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 0.10 (-1.51 to 1.67) | 0.41 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 3.01 (1.28 to 6.93) | 0.37 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 5.58 (1.19 to 23.50) | 0.41 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.28 (0.00 to 11.68) | 0.55 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.36 (0.52 to 3.62) | 0.51 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.46 (0.01 to 32.21) | 0.60 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.29 (0.64 to 2.69) | 0.36 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 2.42 (0.34 to 24.33) | 0.39 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 9.80 (3.17 to 46.52) | 0.11 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 14.48 (3.94 to 86.46) | 0.10 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.08 (1.10 to 3.97) | 0.38 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.72 (0.05 to 11.13) | 0.50 |
Trials
- PB119A Phase III, Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects2020 · 273 randomized · 24 weeks
- NCT04504396A Multicenter, Randomized, Double-blinded, Placebo-controlled Trial Comparing the Efficacy and Safety of PB-119 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Alone2020 · 620 randomized · 24 weeks